LB Pharmaceuticals hires Minako Pazdera as general counsel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
January 21, 2026 8:00 AM ESTNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (LB Pharmaceuticals or the Company) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel.
Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance.
We are delighted to welcome Minako to LB Pharmaceuticals, said Heather Turner, Chief Executive Officer. Dr. Pazdera has broad expertise encompassing both financial and strategic transactions, as well a deep understanding of intellectual... More
